Retinoblastoma: Symptoms, Survival Rates, and Treatment

What is Retinoblastoma?

Retinoblastoma is a rare malignant tumor of the eye that almost exclusively affects young children, typically developing before the age of 5. It arises in the retina, a specialized light-sensitive tissue lining the back of the eye. This tissue detects light and color and transmits visual information to the brain through the optic nerve.

Retinoblastoma is the most common primary intraocular malignancy in children, accounting for approximately 3% of all childhood cancers. It occurs in roughly 1 in 15,000–18,000 live births and affects boys and girls equally, with no significant racial or geographic predisposition in incidence.

In the majority of patients, the tumor affects only one eye (unilateral), but approximately 1 in 3 children presents with involvement of both eyes (bilateral). Bilateral disease is always associated with a heritable genetic mutation.

Key Warning Signs

The most recognizable early sign of retinoblastoma is a white reflex visible in the pupil (leukocoria). This is usually noticed in low-light conditions or in flash photographs, where the pupil appears white or yellowish-white instead of showing the normal red reflex. Other signs and symptoms include:

• Strabismus (crossed or misaligned eyes)
• A change in the color of the iris (colored part of the eye)
• Redness, soreness, or swelling of the eyelids
• Reduced vision, up to and including complete blindness in the affected eye
• Painful eye (when complicated by glaucoma)

🔍 Parents should be aware: A white or yellowish glow in one or both pupils in photographs, particularly those taken with flash, may signal retinoblastoma. This symptom requires immediate medical evaluation.

---

Survival Rates

Retinoblastoma is often curable, particularly when diagnosed early. When detected and treated promptly, outcomes are generally excellent in high-income countries:

• In specialized pediatric oncology centers, survival rates approach 95% or higher
• In the majority of early-stage cases, vision can be preserved in the affected eye
• When the tumor is confined to the eye (intraocular disease), long-term cure is the norm rather than the exception

However, if retinoblastoma is not diagnosed and treated promptly, it may spread to surrounding tissues and metastasize (metastases) to other parts of the body. This can include the brain, bones, and lymph nodes, making the condition significantly harder to treat and potentially life-threatening.

In low- and middle-income countries, where access to specialized pediatric care may be limited and diagnosis often occurs later, survival statistics are unfortunately considerably worse. Globally, an estimated 40–70% of children with retinoblastoma in low-income settings die from the disease. Early detection remains the single most important factor in survival.

---

Causes

Retinoblastoma develops because of mutations in the RB1 gene, a tumor suppressor gene located on chromosome 13 at position 13q14. Under normal circumstances, the RB1 gene produces the retinoblastoma protein (pRb), which plays a critical role in regulating cell growth and preventing uncontrolled cell division. When both copies of the RB1 gene are inactivated or lost (a concept known as the “two-hit hypothesis” proposed by Alfred Knudson in 1971), retinal cells lose this critical brake on proliferation and develop into a tumor.

Retinoblastoma can be broadly classified into two main forms:

The inheritance pattern of heritable retinoblastoma is autosomal dominant with incomplete penetrance:

• Autosomal: The RB1 gene is located on a non-sex chromosome (chromosome 13), so the condition affects males and females equally.
• Dominant: Inheriting a single defective copy of RB1 (from one parent) is sufficient to markedly increase the risk of tumor development.
• Incomplete penetrance: Carrying the mutated gene does not guarantee that a tumor will develop. Penetrance is approximately 90%, so a small proportion of carriers never develop retinoblastoma.

Heritable Form

In heritable retinoblastoma, the germline mutation in RB1 is present in every cell of the body from conception. This first mutation is inherited (or arises spontaneously in the egg or sperm). A second somatic mutation in the remaining functional copy of RB1 in a retinal cell triggers tumor development.

Key features of the heritable form include:

• Accounts for approximately 40% of all retinoblastoma cases (~25% bilateral, ~15% unilateral)
• Bilateral or multifocal disease is virtually always heritable
• Age at diagnosis is typically within the first year of life for bilateral cases
• Affected individuals carry an elevated risk of developing non-ocular cancers throughout life, including:
  • Pineoblastoma (so-called “trilateral retinoblastoma” when occurring with bilateral RB)
  • Osteosarcoma (bone cancer)
  • Soft tissue sarcomas
  • Melanoma
  • Other epithelial cancers

The cumulative risk of developing a second primary tumor is approximately 6%. However, this risk increases fivefold if radiotherapy is used to treat the primary tumor, which is a critical consideration in treatment planning.

Sporadic Form

Non-heritable (sporadic) retinoblastoma involves two acquired somatic mutations occurring sequentially in a single retinal cell, with no germline involvement. As a result:

• It is always unilateral (involving one eye only)
• It cannot be transmitted to children
• There is no significantly elevated risk of non-ocular cancers
• Siblings and offspring carry no greater risk than the general population

In cases of unilateral retinoblastoma with no family history of the disease, the tumor is presumed to be non-heritable, and the risk of the condition occurring in a sibling or child of the patient is estimated at approximately 1 in 100 (1%). Genetic testing can help clarify whether an apparently unilateral, non-familial case carries an underlying germline mutation.

Almost 90% of unilateral retinoblastoma cases are non-heritable in origin.

---

Symptoms

Leukocoria (White Pupillary Reflex)

The most common and most important early sign of retinoblastoma is leukocoria, an abnormal white reflection from the pupil. This is sometimes described as a “cat’s eye” reflex or “white glow”.

• Under normal circumstances, when light strikes the pupil, it produces a red reflex (due to the rich blood supply of the retina)
• In retinoblastoma, the growing tumor mass behind the pupil causes the pupil to appear white, cream, or yellowish-white when illuminated

Leukocoria is often first noticed by parents in flash photographs, where one or both eyes show a white glow instead of the normal red-eye effect. It may also be visible under certain lighting conditions. This sign should always prompt immediate referral to a pediatric ophthalmologist.

Other Common Symptoms

• Strabismus (crossed or misaligned eyes, also called squint) is the second most common presenting sign and often indicates macular involvement.
• Change in iris color: heterochromia or irregular iris coloration caused by tumor invasion.
• Red, inflamed, or swollen eyes, particularly when associated with secondary glaucoma (increased eye pressure caused by the tumor).
• Excessive tearing (epiphora).
• Reduced vision may appear in infants as a failure to visually track objects, poor depth perception, or repeated falls.
• Limited eye movements, which are more common when both eyes are affected.
• Eye pain, which often occurs when glaucoma develops as a secondary complication.
• Proptosis (bulging eye): a sign of advanced extraocular spread. It remains common in low-income countries at first presentation.

---

Complications

Local and Metastatic Spread

Without timely treatment, retinoblastoma can extend beyond the eye:

• Optic nerve invasion: The tumor can grow along the optic nerve into the subarachnoid space and reach the brain. This represents one of the most dangerous routes of spread.
• Orbital extension: the tumor breaks through the sclera, the white outer coat of the eye, into the surrounding orbital tissues.
• Systemic metastases, which spread to regional lymph nodes, liver, lungs, bones, and brain, indicate a significantly worse prognosis once metastatic disease is established.

Blindness

Retinoblastoma can cause permanent blindness in the affected eye if treatment is delayed or if the tumor is so advanced that preservation of vision is impossible. In bilateral cases, the risk of visual impairment in both eyes must be carefully weighed against treatment options.

Risk of Second Primary Tumors (Heritable Form)

Children with the heritable form of retinoblastoma face a significantly elevated lifelong risk of developing second primary malignancies, regardless of the treatment they receive. This risk is substantially increased if radiotherapy was used to treat the original tumor, and it persists throughout adulthood. Regular long-term oncological surveillance is therefore essential for all survivors of heritable retinoblastoma.

Psychological and Developmental Impact

The diagnosis of a childhood cancer, potential loss of vision, and the demands of treatment carry significant psychological consequences for the child and their family. Psychosocial support, which includes age-appropriate psychological counseling for the child as well as support for parents and siblings, is an integral part of comprehensive retinoblastoma care.

---

When to Contact a Doctor

Seek prompt medical evaluation by a pediatrician or pediatric ophthalmologist if you notice any of the following in your child:

• A white spot or white glow in the pupil, even if it only appears in photographs or under certain lighting conditions.
• Any visual disturbance, which in young children may manifest as:
  • Repeated unexplained falls or clumsiness
  • Holding toys or books very close to the face
  • Difficulty navigating familiar environments
  • Failure to visually track moving objects
• Persistent strabismus (squinting or crossed eyes)
• Redness, swelling, or pain in or around the eye that does not resolve
• Any change in the appearance of the pupil or iris

✅ Early detection is the most powerful tool we have. Do not adopt a “wait and see” approach if any of these signs are present. A timely diagnosis can mean the difference between a cure that preserves vision and a life-threatening situation.

---

Diagnosis

Clinical Eye Examination

An ophthalmologist can identify the characteristic white pupillary reflex using an ophthalmoscope or a red reflex test. This test is a simple, non-invasive screening tool routinely performed as part of newborn and well-child examinations. The red reflex test involves shining a light into the pupil from a short distance; an abnormal white, yellow, or asymmetric reflex warrants immediate specialist referral.

Detailed examination of the fundus (back of the eye) under general anesthesia is typically required in young children to allow thorough assessment without movement artifacts. This allows precise mapping of tumor size, location, number of foci, and extent of involvement.

Imaging Studies

When retinoblastoma is suspected, further imaging is performed to confirm the diagnosis and assess the extent of disease:

• Ocular ultrasound involves applying the ultrasound probe to the closed eyelid. This technique is highly useful for detecting intraocular calcification, which is present in the vast majority of retinoblastomas, and for assessing tumor dimensions.
• MRI (Magnetic Resonance Imaging) is the preferred modality for evaluating:
  • Optic nerve involvement.
  • Extraocular extension.
  • Intracranial spread (including pineal region disease in heritable cases).
  • Brain and spinal cord assessment.
• CT scan: Less preferred because of radiation exposure in children. It may still be used in specific circumstances, however.
• Bone marrow biopsy and lumbar puncture: these procedures are performed when systemic metastasis is suspected.

Genetic Testing

Genetic testing for RB1 germline mutations is recommended for:

• All children with bilateral retinoblastoma (always heritable)
• Children with unilateral retinoblastoma and a positive family history
• Siblings and parents of affected children
• Offspring of retinoblastoma survivors

Identification of a germline mutation has critical implications for genetic counseling, family screening, long-term surveillance planning, and reproductive decisions.

Staging

Retinoblastoma is classified using the International Classification of Retinoblastoma (ICRB), which assigns tumors to groups A through E based on size, location, and associated features (vitreous or subretinal seeding):

Groups A–C generally carry a better prognosis and are more amenable to eye-preserving treatments. Group E tumors often require enucleation (surgical removal of the eye).

---

Treatment

The treatment approach for retinoblastoma depends on several key factors:

• Laterality (one or both eyes involved)
• Stage and group of the tumor at diagnosis
• Whether disease is intraocular or extraocular
• Patient’s overall health and age
• Heritable vs. sporadic form

The primary goals follow this order of priority: first, save the child’s life; second, preserve the eye; and third, preserve useful vision.

Intraocular Disease (Confined to the Eye)

1. Laser Photocoagulation

A laser is used to destroy the blood vessels supplying the tumor, cutting off its nutrient supply. It is most suitable for small tumors located away from the macula and optic nerve. Administered under general anesthesia.

2. Cryotherapy (Freezing)

A probe is used to freeze and destroy small peripheral tumors. Like photocoagulation, it is used for small lesions, often in combination with chemotherapy. Administered under general anesthesia.

3. Chemotherapy

Chemotherapy is a cornerstone of modern retinoblastoma management and may be used in several ways:

• Intravenous (systemic) chemotherapy reduces tumor size before focal treatment, known as “chemoreduction”, or prevents metastatic spread. It commonly uses a combination of carboplatin, vincristine, and etoposide.
• Intra-arterial chemotherapy (IAC) involves guiding a catheter through the femoral artery to the ophthalmic artery. This method delivers high-dose chemotherapy, typically melphalan, directly to the eye while minimizing systemic exposure. As a result, IAC has transformed eye-preserving treatment for advanced intraocular disease.
• Intravitreal chemotherapy: A treatment involving the direct injection of chemotherapy drugs, such as melphalan or topotecan, into the vitreous cavity. This approach is used for vitreous seeding that does not respond to other therapies.

4. Brachytherapy (Plaque Radiotherapy)

For tumors that are not too large and have not responded adequately to other treatments, small radioactive plaques (typically containing iodine-125 or ruthenium-106) are surgically sutured over the tumor on the outer surface of the eye and left in place for several days to deliver a targeted dose of radiation, then removed. This approach largely avoids the long-term risks associated with external beam radiotherapy.

5. External Beam Radiotherapy (EBRT)

Historically used extensively, EBRT is now used sparingly, particularly in children with heritable retinoblastoma. This shift is due to its association with a significantly increased risk of second primary malignancies in the irradiated field. When used, modern techniques (such as intensity-modulated radiotherapy, proton beam therapy) minimize radiation exposure to surrounding tissues.

Surgical Treatment: Enucleation

Enucleation (surgical removal of the affected eye) is indicated when:

• The tumor is so large or advanced that there is no realistic hope of preserving useful vision
• The eye is blind and painful (e.g., due to neovascular glaucoma)
• Other treatments have failed
• The eye shows features of group E disease

While the prospect of removing a child’s eye is distressing, enucleation remains one of the most effective ways to cure retinoblastoma and can be life-saving. Children adapt remarkably well to monocular vision, and a well-fitted ocular prosthesis (artificial eye) provides an excellent cosmetic result. Psychological support for both child and family is essential throughout this process.

Extraocular and Metastatic Disease

When disease has spread beyond the eye, treatment becomes significantly more aggressive and complex, typically involving:

• High-dose systemic chemotherapy
• Autologous stem cell transplantation
• Radiation therapy (to affected sites)
• Multidisciplinary oncological management

Outcomes for metastatic retinoblastoma remain poor, emphasizing the critical importance of early diagnosis.

Follow-Up and Long-Term Surveillance

All children treated for retinoblastoma require regular long-term follow-up:

• Frequent eye examinations under anesthesia in the first years after treatment to monitor for local recurrence
• Annual ophthalmological review throughout childhood
• For children with heritable disease: lifelong surveillance for second primary tumors
• Regular imaging (MRI) as clinically indicated
• Genetic counseling for the patient’s family and, eventually, for the patient themselves when considering having children

---

Sources and Bibliography

• Retinoblastoma – Husnain Ishaq; Bhupendra C. Patel. StatPearls, NCBI
• MedlinePlus – Retinoblastoma
• NHS – Retinoblastoma
• MSD Manuals – Retinoblastoma in Pediatric Age
• American Academy of Ophthalmology – Retinoblastoma
• Dimaras H et al. – Retinoblastoma. Nature Reviews Disease Primers, 2015. PubMed
• Knudson AG – Mutation and cancer: statistical study of retinoblastoma. PNAS, 1971. PubMed
• Children’s Oncology Group – Retinoblastoma Guidelines
• National Cancer Institute – Retinoblastoma Treatment (PDQ®)